We treated genetically mast cell-deficient WCB6F1 Sl/Sld mice and the congenic normal (WCB6F,-+/+) mice with the c-kit ligand recombinant rat stem cell factor" (rrSCF'"; 100 ,ug/kg per d, subcutaneously) or with vehicle for 21 d, then passively sensitized the mice with anti-dinitrophenol3 40 immunoglobulin E (IgE) antibodies, and 1 d later measured the changes in heart rate, pulmonary dynamic compliance, and pulmonary conductance, and assessed the death rates associated with intravenous challenge of these animals with specific antigen. rrSCF 4 treatment induced the development of mast cells in SI/Sid mice, and these mice exhibited tachycardia, but not death, after challenge with IgE and antigen. rrSCF'" treatment induced mast cell hyperplasia in + /+ mice, but the cardiopulmonary changes associated with passive anaphylaxis in these mice were virtually indistinguishable from those observed in control +/+ mice treated with vehicle instead of rrSCF'".
Introduction
Three groups simultaneously reported that the S/ locus on mouse chromosome 1 0 encodes a new growth factor that represents a ligand for the c-kit receptor (1) (2) (3) (4) (5) (6) (7) . This growth factor has been designated stem cell factor (SCF;' references 3-5), mast cell growth factor (MGF; references 1 and 2), kit ligand (KL; reference 6), and steel factor (SLF; references 8 and 9). The wild-type SCF is produced as a transmembrane protein (3, 4, 6, 7, 9-1 1 ), of which two major alternatively spliced forms have been described in the mouse ( 11) . The longer of these consists of an -189-amino acid extracellular ligand domain, May, 1993. an -2 1-amino acid transmembrane domain, and an -36-amino acid intracytoplasmic tail; proteolytic cleavage of the extracellular domain of the membrane-associated product releases an -164-amino acid biologically active soluble form of SCF ( 11 ) .
A large body of in vitro and in vivo data indicate that SCF can critically regulate mast cell development and secretory function (12, 13) . WCB6F,-SI/Sld mice, which have mutations at the SI locus that result in a failure of production of transmembrane SCF (2, 5, 6, 1 1), virtually lack tissue mast cells (14) . However, daily subcutaneous injection of S/S1" mice with recombinant rat SCF'64(rrSCF'64) for 21 d results in the development of many mast cells in the skin at the injection site (5, 15) . rrSCF 164 can promote the tissue localization and/ or survival of mouse mast cell precursors in vivo (5, 15) , the proliferation ofboth immature and mature mouse mast cells in vitro (16) , the maturation of immature mouse mast cells in vitro (16, 17) , and mouse mast cell maturation and proliferation in vivo (5, 15, 16) . In rats, intravenous treatment with rrSCF'64 results in hyperplasia of both "connective tissue-type mast cells" (CTMC) , such as those in the skin and peritoneal cavity, and "mucosal mast cells" (MMC), such as those in the mucosa of the ileum or glandular stomach ( 15 ) . rrSCF 164 also can directly induce c-kit-dependent mast cell activation when injected intradermally in mice ( 18) , can directly stimulate serotonin release by purified mouse peritoneal mast cells in vitro ( 19) , and, at even lower concentrations, can significantly augment serotonin release by mouse peritoneal mast cells stimulated via their surface FcRI ( 19) . SCF not only influences mast cell development and function in rodents, but also in humans and other primates. Administration of recombinant human SCF (rhSCF) subcutaneously to baboons (Papio species) or cynomolgus monkeys (Macaca fascicularis) in vivo induces mast cell hyperplasia in many anatomical sites (20) . rhSCF also can promote the development of human mast cells in vitro, particularly when rhSCF is used as the only exogenous cytokine (21) (22) (23) (24) . Finally, studies of isolated human mast cells demonstrate that concentrations of rhSCF in the I -1 0-ng/ ml range can induce low levels ofmediator release from skin mast cells (25) , and that brief preincubation with even lower concentrations of rhSCF can significantly augment FcRI-dependent mediator release by skin (24) or lung (26) mast cells.
Given the known spectrum of biological effects of SCF on mast cell development and function, we felt that it would be of some interest to determine whether prolonged administration ofSCF influenced either the mast cell activation, the physiological changes, or the mortality associated with a systemic IgE-dependent biological response in vivo. We therefore administered rrSCFlM or vehicle daily for 21 d to mast cell-deficient WCB6F,-Sl/Sld mice and to the congenic normal WCB6F,-+/+ mice. We then attempted to elicit IgE-dependent passive anaphylaxis in these animals, and evaluated the characteristics ofthese responses. Some ofthese results have been presented in abstract form (27) .
Methods
Animals. We studied male genetically mast cell-deficient WCB6F1-SI/ Sld (SlS//d) mice and the congenic normal (WCB6F,-+/+): (WC/ ReJ-Sl/+ X C57BL/6J-SldI+)F1-(Sl/Sld, +/+) mice (The Jackson Laboratory, Bar Harbor, ME) that were 12-16 wk old (25-35 g body weight) at the beginning ofthe experiment. The Si/Sid mice have mutations at the SI locus on chromosome 10, which encodes a ligand (SCF) for the c-kit tyrosine kinase growth factor receptor (1) (2) (3) (4) (5) (6) (7) . The Sl mutation is a deletion of all coding sequences (2, 5, 6) , whereas S1d produces a truncated transcript (5, 1 1 ) encoding almost all ofthe extracellular domain of SCF but lacking the coding sequence for the transmembrane and intracellular domains of the wild-type protein ( 11) . Sl/Sld mice are anemic, lack melanocytes in the skin, are sterile, and virtually lack tissue mast cells (4, 12, 14) . The skin ofadult S/Sld mice contains < 0.5% the number of mast cells present in the skin of the congenic +/+ mice, and no mast cells whatsoever are identifiable in the trachea, lungs, or multiple other organs or anatomical sites (4, 12, 14) . However, apart from defects in responses significantly influenced by mast cells, the expression ofimmunological and inflammatory reactions in Sl/Sld mice is similar or identical to that in the congenic normal animals ( 12).
Reagents. rrSCF'4, representing essentially the entire extracellular portion of the transmembrane protein, was purified from Escherichia coli and modified by the covalent attachment ofpolyethylene glycol (5, 15) Cdy., and pulmonary resistance were calculated from the recordings of volume, flow, and pressure using standard techniques (32) . Baseline values of HR, Cd,,,, and GL were determined 20-30 min after preparation of the animals for recording pulmonary parameters. Histologic studies. The presence of tissue mast cells and their state of activation were assessed in 1 Lm, Epon-embedded, Giemsa-stained sections (30, 33, 34) . Tissues were removed and fixed as previously described (31, 33, 34) , either immediately after death induced by DNP-HSA challenge, or after death by cervical dislocation 60 min after challenge. Sections of dermis at subcutaneous injection sites (5, 15) , dermis ofear skin (31, 34) , trachea (30) , and peribronchial tissue (30, 31 ) were evaluated for mast cell numbers as previously described. Mast cells also were quantified in sections of the mid right lower lobe of the lung, extending to the pleura, the mid free wall of the left ventricle of the heart, the middle ofa hepatic lobe, the middle ofthe spleen, the mid portion of the forestomach (mast cells were quantified in the submucosa), and the mid glandular stomach (mast cells were quantified separately in the mucosa, submucosa, and muscularis propria). Sections were coded so that the observer was not aware ofthe identity ofindividual specimens, and examined at X400 by light microscopy. Mast cells were classified as "extensively degranulated" (> 50% of the cytoplasmic granules exhibiting fusion, staining alterations, and/or extrusion from the cell), "moderately degranulated" ( 10-50% of the granules exhibiting fusion or discharge), or "normal" (31, 33, 34 
Results
Chronic treatment with rrSCF'64 induces the development of mast cells in Sl/Sld mice and mast cell hyperplasia in the congenic +/+ mice. The numbers ofmast cells in various tissues of rrSCF'64-or vehicle-treated mice were assessed histologically in specimens that had been obtained and fixed immediately upon completion of the physiological studies in these animals. Even though extensively degranulated mast cells can occasionally be difficult to identify, this problem occurs primarily when counts are performed at long intervals after mast cell activation (34) rather than, as in this study, only I h after stimulation (31 ) . In the present study, numbers of mast cells in the ears, trachea, lungs, heart, spleen, liver, or skin injection sites were not significantly lower in mice challenged with 1,000 Mug of DNP-HSA than in corresponding mice challenged with saline alone. In rrSCF '64-treated +/+ mice, -21% fewer mast cells were counted in the bronchi of mice challenged with 1,000 Mg of DNP-HSA than in those challenged with saline (P < 0.05 by Student's two-tailed t-test). Because the data from mice of a given genotype and rrSCF'64 or vehicle treatment status that had been challenged with 0.9% NaCl or with different doses of DNP-HSA were quite similar, data from mice challenged with 0-1000 gg DNP-HSA were pooled for presentation in Table I . Analysis of mast cell numbers in the tissues of0.9% NaCl-challenged rrSCF '64-or vehicle-treated mice that had not been used for physiological measurements gave similar results (data not shown).
In confirmation of our previous study (15) , +/+ mice treated with rrSCF '64 exhibited 48-fold higher densities of mast cells in the skin at the subcutaneous injection site than did the vehicle-treated mice. rrSCF164 treatment of +/+ mice also resulted in an almost 50-fold elevation of mast cell densities in the spleen. The results were less striking in other anatomical sites. However, rrSCF'64 treatment resulted in statistically significant increases in peribronchial, tracheal, and cardiac mast cells (increases of 80, 100, and 170%, respectively), 50-90% increases in mast cell densities in the ear skin, forestomach, and glandular stomach mucosa and submucosa, and the appearance of small numbers of mast cells in the liver and pulmonary parenchyma, two sites that lacked mast cells in the vehicletreated +/+ mice. Of all the sites examined, only the muscularis propria of the stomach did not exhibit a statistically significant increase in mast cells in response to rrSCF'64 treatment.
Vehicle-treated Sl/Sldmice lacked any histologically detectable mast cells (data not shown). By contrast, mast cells were detectable in all of the anatomical sites examined in rrSCF 164_ treated Sl/Sld mice ( Table I) . As in rrSCF'64-treated +/+ mice, the most striking effects occurred in the skin at the injection site and in the spleen, which exhibited mast cell densities that were 26% or approximately two-fold, respectively, those in the corresponding sites in rrSCF '64-treated +/+ mice. rrSCF 164-treated Sl/Sld mice had 3.7-fold the density ofpulmonary parenchymal mast cells and 7.3-fold the density ofhepatic mast cells, as did rrSCF '64-treated +/+ mice. In contrast, in other anatomical sites, the densities of mast cells in the rrSCF '64-treated SI/Sld mice were much less than those in the rrSCF'64-treated +/+ mice. For example, values in the ear skin, trachea, bronchus, or heart of rrSCF '64-treated S1/Sd mice were 0.2, 0.1, 0.06, or 1. 1% those in rrSCF 164-treated +/+ mice. Chronic treatment with rrSCF'64 does not alter baseline valuesfor HR, Cdyn, or GL in 51/SI" or +/+ mice. As noted in our previous study (30) , the baseline values for HR and Cdyn in WCB6F,-+/+ mice were higher (-15%) than those in the congenic S1/S1d mice (Table II) Fig. 1 A) , or by the maximum percent change in these measurements during the first 10 min after challenge (Table  III) , vehicle-treated S1/Sd mice challenged with 200 or 1,000 ,qg of DNP-HSA gave responses that were little or no different than those of vehicle-treated S/Sld mice challenged with saline. And none of these mice died as a result of antigen challenge (Table IV) .
Chronic treatment with rrSCFF64 permits S1/Sld mice to Table III) . Furthermore, none of the rrSCF '64-treated S1/ S1d mice died as a result of antigen challenge (Table IV) . Chronic treatment with rrSCF'64 does not increase the severity of IgE-dependent passive anaphylaxis in WCB6F1-+/+ mice. We showed previously that intradermal injection of rrSCF'64 induces c-kit-dependent mast cell activation in mice ( 18) , and that short-term incubation ofmouse peritoneal mast (Fig. 1, B and D, and Table III) . Indeed, the only significant differences occurred at 5 ,og DNP-HSA, with greater responses in the +/+ than in the SlS/1d mice (P = 0.0124 or 0.0048 when compared by AN-OVA over the first 20 or 60 min after challenge, respectively). In marked contrast, the pulmonary responses in the +/+ mice were significantly greater than those in the Sl/Sld mice at all three doses of antigen challenge (Fig. 1, B (Fig. 4). Figs. 2-4 present the results obtained in those anatomical sites containing > 10 mast cells/mm2 (see Table I ). This analysis established several points. First, in the absence of challenge with IgE and antigen, rrSCF '64-treated mice did not exhibit histological evidence of significant mast cell activation. Thus, in +/+ mice challenged with saline (0 ug DNP-HSA), there were no statistically significant differences in the extent of mast cell activation in rrSCF'64-vs. vehicle-treated mice, even at the skin sites that had been repeatedly injected with rrSCF 4 (Figs. 2 and 3) , nor was there significant mast cell activation in the tissues of rrSCF 164-treated Sl/Sld mice challenged with 0 Mug DNP-HSA (Fig. 4) . Similar results were obtained in 0.9% NaCl-challenged +/+ or S/5Sld mice that had not been used for physiological measurements (data not shown).
Second, an antigen dose-response effect on mast cell activa- Epon-embedded, Giemsa-stained sections were examined as described in the text to assess the extent of mast cell activation in the tissues. Data, which are expressed as mean±SEM, are from the same mice shown in Fig. 1 (Fig. 2) . This result, while unexplained, may be of some interest, particularly since the death rate in rrSCF "-e-treated WCB6F1-+/+ mice challenged with 200 pg of DNP-HSA was significantly higher than that in rrSCF "6-treated +/+ mice challenged with 1,000 pg of DNP-HSA (Table IV) .
Third, chronic treatment with rrSCF'64 appeared to alter the ability of some mast cell populations to respond to IgE-dependent activation, but the nature of this effect differed in different anatomical sites. For example, the extent of mast cell activation at the cutaneous injection site was substantially and significantly (P < 0.001 ) less in rrSCF'64-treated than in vehicle-treated +/+ mice at every dose ofantigen challenge. And at the 5-,pg dose of antigen challenge, rrSCF'6-treated +/+ mice also exhibited significantly less mast cell activation than did vehicle-treated + /+ mice in ear skin, trachea, and spleen (Figs.  2 and 3) . However, challenge with 5 pg ofDNP-HSA produced slightly, but significantly, more gastric mast cell activation in rrSCF'64-treated +/+ mice than in the corresponding vehicletreated animals (Fig. 3) .
Finally, the pattern of mast cell activation observed in the tissues of rrSCF'64-treated SI/Sid mice was different than that seen in the rrSCF 164-treated congenic normal mice. Compared with rrSCF'64-treated +/+ mice, rrSCF'64-treated Sl/Sld mice exhibited at rrSCF'64 injection sites somewhat less mast cell activation at 5 ,g of DNP-HSA challenge but somewhat more activation at 1,000 pg of DNP-HSA (Fig. 4) . Similarly, in the submucosa of the glandular stomach, rrSCF'64-treated Sl/Sld mice exhibited slightly less mast cell activation than did the corresponding +/+ mice at 5 ug of DNP-HSA challenge, but exhibited significantly more activation than did the +/+ mice after challenge with 200 or 1,000 ,g ofDNP-HSA (Fig. 4) . The reasons for the differences in the extent of IgE-dependent acti- Table V) that were not significantly different than those observed in the corresponding groups of 51151d mice that had been treated with rrSCF'64 or vehicle for 21 d (Table III) . In +/+ mice, the maximum changes in HR, Cdyn, or GL observed after challenge with 1,000 pg of DNP-HSA were virtually identical in mice treated for 22 d with rrSCF'64 or vehicle (Table V) . However, the maximum intensity of the pulmonary responses in the +/+ mice that had been treated with rrSCF'64 or vehicle for 22 d was slightly but significantly greater than that in the corresponding groups of +/+ mice that had been treated with rrSCF'64 or vehicle for 21 d (compare data in Tables III and V) . Death rates in +/+ mice were 1 of4 or 3 of 5 in mice treated for 22 d with rrSCF'64 or vehicle, respectively, and in the corresponding groups of Sl/Sld mice were 0 of 5 or 0 of4, respectively. These results are very similar to those obtained in mice treated with rrSCF'64 or vehicle for 21 d (Table IV, Epon-embedded, Giemsa-stained sections were examined as described in the text to assess the extent of mast cell activation in the tissues.
Data, which are expressed as mean±SEM, are from the same mice shown in Fig. 1 ( 19) . However, in isolated human skin mast cells, 24-h preincubation with rhSCF, in contrast to short-term ( 10 min to 1 h) preincubation with the cytokine, did not augment the ability of these cells to release mediators in response to IgE-dependent activation (25) . In the present study, morphological assessment indicated that the effects of chronic treatment with rrSCF'" on the extent of IgE-dependent mast cell activation in vivo may vary both in magnitude and in sign in anatomically distinct populations of mast cells. Thus, in +/+ mice challenged with 5 ,g of DNP-HSA, rrSCF'" treatment was associated with greatly reduced IgE-dependent mast cell activation in the skin, trachea, peribronchial tissue, spleen, and forestomach, but with slightly enhanced IgE-dependent mast cell activation in the glandular stomach.
We also found that the dermal mast cells that had been chronically exposed to the highest concentrations of rrSCF 64, i.e., those at the actual rrSCF'" injection sites, exhibited a more dramatic reduction in responsiveness to IgE 1±3% extensively activated mast cells in vehicle-vs. rrSCF'64-treated mice, a nine-fold difference). However, the mast cell density at these sites in rrSCF '64-treated mice was 48-fold that in vehicle-treated animals. As a result, it is possible that the amount of mast cell-associated mediators released at the rrSCF'64-treated sites actually exceeded that at the vehicletreated sites.
The concept that the large mast cell populations at the rrSCF '6 extensively activated mast cells, respectively). Thus, in rrSCF'64-treated +/+ mice, the highest mortality rate due to passive anaphylaxis occurred in mice challenged with the dose of antigen that produced the most extensive activation of the large mast cell population at the rrSCF 164 injection sites. Unfortunately, we have no data that can explain why 200 ,g ofDNP-HSA produced more activation of this mast cell population than did 1,000 jig of DNP-HSA.
Furthermore, we do not know why fatalities due to passive anaphylaxis in rrSCF'64-treated +/+ mice challenged with 1,000 ,ug of DNP-HSA were so low compared with those in identically challenged vehicle-injected +/+ mice. Several lines ofevidence (30, 31 ) , including the present results, indicate that the death associated with at least some IgE-dependent passive anaphylaxis reactions in mice is mast cell dependent. Yet the rrSCF'64-treated mice had significantly higher mast cell densities than the vehicle-treated mice in almost all anatomical sites tested. Moreover, at all anatomical sites other than the subcutaneous injection sites, the extent of mast cell activation that was produced by challenge with 1,000 gg of DNP-HSA was virtually identical in both the rrSCF164 and the vehicle treatment groups. And as suggested above, the low level ofIgE-dependent activation of the large population of mast cells at the rrSCF'64 injection sites may have resulted in the release of the same or greater amounts of mediators, as did the more extensive degree of activation of the much smaller mast cell population at the corresponding vehicle-injected sites.
On the other hand, it is not known whether the spectrum and amounts ofmediators produced upon IgE-dependent mast cell activation are identical in rrSCFlM4-or vehicle-treated +/+ mice, nor do we understand the mechanism of death in mice experiencing IgE-dependent passive anaphylaxis. But whatever the explanation for the lower death rates in rrSCF'4-vs. vehicle-injected mice, our analysis ofthe extent of mast cell activation, the cardiopulmonary changes, and the mortality associated with IgE-dependent passive anaphylaxis in rrSCF 164_ or vehicle-treated normal mice indicates that prolonged treatment with this cytokine does not augment, and in certain respects may diminish, the severity of the reaction.
